{"entity":{"id":"nct07809906","kind":"trial","name":"Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression","aka":[],"tldr":"A phase 1 trial of ORM-1153 run by Orum Therapeutics USA, Inc., now recruiting.","summary":"Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression is a phase 1 interventional study registered as NCT07809906 by Orum Therapeutics USA, Inc., with 42 participants planned, started 2026-09-23. Conditions recorded: CD123+ Acute Myeloid Leukemia. Interventions recorded: ORM-1153.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07809906","url":"https://clinicaltrials.gov/study/NCT07809906"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["orm-1153"],"companies":["orum-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07809906","phase":"1","setting":"Phase 1 First-in-Human Multi-Region Clinical Trial of ORM-1153 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Other Hematological Malignancies With CD123 Expression","sponsor":"Orum Therapeutics USA, Inc.","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07809906/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"orm-1153","kind":"drug","name":"ORM-1153","route":"/drugs/orm-1153/"}],"company":[{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/"}]}}